[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hip-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hip-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,87,112,133,160,183,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100627511","pericapsular-nerve-group-block-versus-intrathecal-morphine-for-analgesia-after-total-hip-arthroplasty-100627511",false,"NCT07449585","Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty","Comparison of the Efficacy of the Pericapsular Nerve Group (PENG) Block Versus Intrathecal Morphine for Postoperative Analgesia Following Total Hip Arthroplasty","Inclusion Criteria:\n\n* Informed, written consent for study participation.\n* Qualification for elective primary total hip arthroplasty via a posterolateral approach.\n* Age above 18 years.\n* ASA Physical Status I-III.\n* Absence of contraindications to spinal anesthesia.\n* Absence of contraindications to performing a Pericapsular Nerve Group (PENG) block.\n* Absence of contraindications to the administration of the pharmacological agents utilized in the study.\n\nExclusion Criteria:\n\n* Absence of informed consent.\n* Age below 18 years.\n* Psychoactive substance abuse or dependence.\n* Chronic opioid therapy.\n* Contraindications to spinal anesthesia.\n* Contraindications to the Pericapsular Nerve Group (PENG) block.\n* Contraindications to the administration of study medications.\n* Body Mass Index (BMI) above 30 kg\u002Fm\\^2.\n* Pregnancy.\n* History of chronic pain management.","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"NA","The Pericapsular Nerve Group (PENG) block is an effective method for postoperative pain management in patients undergoing primary total hip arthroplasty (THA) via a posterolateral approach. The application of this technique reduces postoperative opioid requirements, thereby limiting the risk of adverse effects associated with systemic opioid administration. Effective pain control and a reduced incidence of side effects may translate into higher patient satisfaction and a decreased length of hospital stay (LOS). The PENG block serves as an effective component of multimodal analgesia and may provide an alternative to intrathecal morphine in patients undergoing primary total hip arthroplasty via a posterolateral approach, where the primary anesthetic technique is spinal anesthesia with hyperbaric bupivacaine.\n\nObjectives\n\n1. To evaluate the efficacy of the PENG block in postoperative pain control and compare its effectiveness with intrathecal morphine administration.\n2. To assess the impact of the PENG block on postoperative opioid consumption in comparison to analgesia achieved via intrathecal morphine.\n3. To analyze the incidence of selected adverse effects associated with systemic opioid administration in patients receiving a PENG block versus those in the intrathecal morphine group.\n4. To evaluate patient satisfaction levels regarding postoperative pain management across the different analgesic modalities.\n5. To analyze the correlation between the type of analgesia employed and the duration of hospitalization.",[26,27,28,29],"Perioperative Analgesia","Hip Replacement, Total","Postoperative Pain","Hip Disease",[31,32,33,34,28,35,36,37],"Pericapsular Nerve Group Block","Intrathecal Morphine","Spinal Anesthesia","Total Hip Arthroplasty","Postoperative Analgesia","Opioid Consumption","Patient-Controlled Analgesia","NOT_YET_RECRUITING","2026-03-01",{"date":41,"type":42},"2026-03-04","ACTUAL",{"date":39,"type":20},{"date":45,"type":20},"2028-12-31",{"name":47,"class":48},"Medical University of Gdansk","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100467071","pediatric-orthopaedic-implant-safety--efficacy-100467071","NCT05361980","Pediatric Orthopaedic Implant Safety & Efficacy","Global Pediatric Orthopaedic Implant Safety & Efficacy Clinical Follow-up Program","Global POISE","Inclusion Criteria:\n\n* Patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. Off-label use is strongly discouraged; however, any and all on- and off-label indications for use of the products in this program will be collected and stratified accordingly\n* Patients must be able to adhere to the required length of follow-up for the endpoints of each individual product\n* Informed consent\u002Fassent is required\n\nExclusion Criteria:\n\n* Patients with a demonstrated sensitivity to metals\n* Patients with an inability to follow a post-operative regimen",true,"0 Years","25 Years",{"count":61,"type":20},4000,"2 Years","OBSERVATIONAL","Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity.\n\nGiven the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy.\n\nProspective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).",[66,67,68,69,70,71,72,73,74,29,75],"Fracture","Lengthening; Leg","Orthopedic Disorder","Deformity of Limb","Deformity; Bone","Implant Breakage","Implant Complication","Hip Dysplasia","Pediatric ALL","Hip Dislocation","RECRUITING","2025-11-19",{"date":79,"type":42},"2025-11-24",{"date":81,"type":42},"2022-01-06",{"date":83,"type":20},"2029-12",{"name":85,"class":48},"University of British Columbia",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":86},"100371979","ace-acetabular-cup-uk-multi-centre-pmcf-study-100371979","NCT04123431","ACE Acetabular Cup UK Multi-centre PMCF Study","A Prospective UK Multi-Centre Post Market Clinical Follow-up Study of the JRI Orthopaedic ACE Acetabular Cup System","Inclusion Criteria:\n\n* Patients deemed suitable for elective primary THR, as per indications in the IFU.\n* Male or female, 18 years or older.\n\nExclusion Criteria:\n\n* Patients who are unable to provide written informed consent.\n* Patients deemed unsuitable for THR, as per contra-indications in the IFU.\n* Patients indicated for THR as a result of trauma (i.e. neck of femur fracture).\n* Patients who are pregnant (exclusion criteria for THR in general).\n* Patients receiving implants other than the approved combination, i.e. an ACE Acetabular Cup System with a JRI femoral stem and head.\n* Patients who are unable to comply with the protocol.",{"count":95,"type":20},225,"A total hip replacement is one of the most successful and cost-effective surgical procedures in orthopaedics, and involves replacing both the hip ball and socket. Its goal is to provide pain relief, allowing the person to return to a normal lifestyle. JRI Orthopaedics have developed the ACE Acetabular Cup System, which has a H-A.C. coating to promote ossoeintegration of the device within the host bone. To increase the surgeons choice and thus suitability for the patient, there is the option of 3 different socket liners (ceramic, polymer or dual mobility).\n\nTo ensure maximum safety and performance of medical devices surveillance of the device should be carried out over the devices lifetime. This study is a 10 year surveillance study to assess the clinical, functional and radiological outcomes of the CE-marked ACE Acetabular Cup System. This is done by examining patient outcomes through questionnaires, reviews of X-rays and complications by patients who have received a total hip replacement using the ACE Acetabular Cup System at participating sites.",[29],[99,100,101],"Total Hip Replacement","Patient reported outcome measures","Post Market Clinical Follow-up \u002F Post Market Surveillance","2025-08-26",{"date":104,"type":42},"2025-09-03",{"date":106,"type":42},"2023-06-06",{"date":108,"type":20},"2035-11",{"name":110,"class":111},"JRI Orthopaedics","INDUSTRY",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":86},"100601840","ace-acetabular-cup-spanish-pmcf-study-100601840","NCT07115732","ACE Acetabular Cup Spanish PMCF Study","A Prospective Single Centre Post Market Clinical Follow-up Study of the JRI Orthopaedic ACE Acetabular Cup System in Spain","Inclusion Criteria:\n\n* Patients deemed suitable for elective primary THR, as per indications in the IFU.\n* Male or female, 18 years to 85 years.\n\nExclusion Criteria:\n\n* Patients who are unable to provide written informed consent.\n* Patients deemed unsuitable for THR, as per contra-indications in the IFU.\n* Patients indicated for THR as a result of trauma (i.e. neck of femur fracture).\n* Patients who are pregnant (exclusion criteria for THR in general).\n* Patients receiving implants other than the approved combination, i.e. an ACE Acetabular Cup System with a JRI femoral stem and head.\n* Patients who are unable to comply with the protocol.","85 Years",{"count":121,"type":20},120,"A total hip replacement is one of the most successful and cost-effective surgical procedures in orthopaedics, involving the replacement of both the hip ball and socket. Its goal is to provide pain relief and enable the patient to return to a normal lifestyle. JRI Orthopaedics have developed the ACE Acetabular Cup System, which has an H-A.C. coating to promote osseointegration of the device within the host bone. To increase the surgeon's choice and thus suitability for the patient, there is the option of three different socket liners (ceramic, polymer, or dual mobility).\n\nTo ensure maximum safety and performance of medical devices, surveillance of the device should be carried out over the device's lifetime. This study is a 10-year surveillance study to assess the clinical, functional, and radiological outcomes of the CE-marked ACE Acetabular Cup System. This will be done by examining patient outcomes through questionnaires, reviews of X-rays, and recording any complications in patients who have received a total hip replacement using the ACE Acetabular Cup System at participating sites.",[29],[99,100,101],"2025-08-22",{"date":127,"type":42},"2025-08-29",{"date":129,"type":20},"2025-08",{"date":131,"type":20},"2036-07",{"name":110,"class":111},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":86},"100604285","phase-4-effectiveness-and-safety-of-the-electrically-powered-orthopedic-exercise-device-on-gait-ability-in-patients-with-hip-joint-diseases-100604285","NCT07147530","Effectiveness and Safety of the Electrically Powered Orthopedic Exercise Device on Gait Ability in Patients With Hip Joint Diseases","Study to Verify Effectiveness and Safety of the Electrically Powered Orthopedic Exercise Device on Gait Ability in Patients With Hip Joint Diseases: Investigator Initiated, Single Center, Single Group Clinical Trial","Inclusion Criteria:\n\n1. Individuals aged 19 or older\n2. Individuals diagnosed with hip osteoarthritis of Kellgren-Lawrence (K-L) Grade 1-4\n3. Individuals diagnosed with avascular necrosis of the femoral head at Association Research Circulation Osseous(ARCO) Stage 1-4\n4. Individuals able to sit at the edge of a bed without assistance and stand for 10 seconds regardless of support\n5. Individuals who are Functional Ambulatory Category (FAC) score of 1-3\n6. Individuals who visited Yongin Severance Hospital, understood the study, and signed informed consent\n7. Individuals who have adequate cognitive ability (Korean Mini-Mental State Examination score ≥ 20)\n\nExclusion Criteria:\n\n1. Individuals who have contraindications for lower limb weight-bearing such as severe joint contractures, osteoporosis, or untreated fractures\n2. Individuals who have progressive or unstable brain diseases or neurological paralysis from stroke\n3. Individuals who have active infections or open wounds hindering device use\n4. Individuals who have significant leg length discrepancies\n5. Individuals who have severe deformities or contractures in the lower extremities\n6. Individuals who have history of poliomyelitis\n7. Individuals inable to maintain seated or standing positions independently\n8. Individuals who have severe spasticity (Modified Ashworth Scale grade ≥ 2)\n9. Individuals who have bone metastases from cancer\n10. Individuals who have severe internal diseases affecting device use (e.g., cardiovascular or respiratory diseases)\n11. Individuals who have cognitive impairments preventing cooperation with device use\n12. Individuals who have complaints of device-related side effects or potential rehabilitation discontinuation\n13. Patients who are determined to be pregnant or potentially pregnant based on the medical interview\n14. Individuals who have any other clinically significant findings deemed inappropriate by the investigator","19 Years",{"count":142,"type":20},30,[144],"PHASE4","Gait is an essential daily activity performed through the complex coordination of the central and peripheral nervous systems and the musculoskeletal system. Gait disorders can negatively affect quality of life, increase the risk of falls, decrease the ability to perform daily activities, and limit physical activity. Various musculoskeletal diseases can cause gait impairment, with hip osteoarthritis and osteonecrosis of the femoral head (ONFH) being the most representative conditions.\n\nVarious interventions can be attempted during the early stages of hip joint disease progression. However, improvement in symptoms does not necessarily indicate a halt in disease progression. As the condition advances in most patients, thinning of the full-thickness hip cartilage or collapse of the femoral head occurs, leading to restricted hip range of motion, weakness of the lower limb muscles and functional deterioration, resulting in the need for total hip arthroplasty.\n\nTHA offers significant improvements in pain relief and function, regardless of the patient's preoperative status, and can reduce long-term healthcare costs. However, performing THA at an early stage with minimal functional improvement is not recommended. Postoperative complications, such as infections, aseptic loosening, and instability, are potential risks, with younger patients aged 45-64 showing higher revision surgery rates compared to those aged 65 and older. This highlights the need for new interventions that can delay the time to surgery while improving gait function and muscle strength.\n\nTherefore, this study aims to explore the clinical feasibility of the Angel Suit H10 (Angelrobotics, Seoul, Korea) by assessing whether wearing the Electrically Powered Orthopedic Exercise Device improves gait function in patients with hip joint diseases, along with evaluating user satisfaction and device safety.",[29],[148,149,150,151],"Rehabilitation","Gait","Wearable robot","Hip joint disease","2025-08-21",{"date":127,"type":42},{"date":155,"type":42},"2025-04-07",{"date":157,"type":20},"2026-04-06",{"name":159,"class":48},"Yonsei University",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":86},"100594718","phase-4-peng-with-lfcb-vs-esp-blocks-for-pediatric-hip-surgery-100594718","NCT07023094","PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery","Comparison of Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block With Lateral Femoral Cutaneous Nerve Block (LFCB) Versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB) in Pediatric Hip Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pediatric patients aged between 2 and 16 years.\n* Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries\n* ASA (American Society of Anesthesiologists) physical status classification: I-III.\n* Written informed consent obtained from the patient's legal guardian(s).\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any of the study medications\n* Presence of infection or inflammation at the intended injection site(s) of regional anesthesia.\n* Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks.\n* Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs.\n* Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation.\n* History of chronic opioid use or known substance abuse.\n* Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.","16 Years",{"count":169,"type":20},60,[144],"This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.",[29,73,173],"Hip Arthropathy","2025-07-08",{"date":176,"type":42},"2025-07-11",{"date":178,"type":42},"2025-06-16",{"date":180,"type":20},"2026-06-30",{"name":182,"class":48},"Poznan University of Medical Sciences",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100364703","mdr---pmcf-study-for-taperloc-complete-stems-100364703","NCT04028687","MDR - PMCF Study for Taperloc Complete Stems","Post Market Clinical Follow up Study to Provide Safety, Performance and Clinical Benefits Data of the Taperloc Complete Stems","Inclusion Criteria:\n\n* Patient must be 18 years of age or older and skeletally mature\n* Patient must be willing and able to sign IRB approved informed consent\n* Patient must have undergone primary or revision hip arthroplasty with the -Taperloc Complete stem according to a cleared indication, which includes the following:\n* Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis\n* Rheumatoid arthritis\n* Correction of functional deformity\n* Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques\n\nExclusion Criteria:\n\n* Off-label use\n* Infection\n* Sepsis\n* Osteomyelitis\n* Uncooperative patient or patient with neurologic disorders who are incapable of following directions\n* Osteoporosis\n* Metabolic disorders which may impair bone formation\n* Osteomalacia\n* Distant foci of infections which may spread to the implant site\n* Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram\n* Vascular insufficiency, muscular atrophy, or neuromuscular disease\n* Patient is known to be pregnant or nursing\n* Patient is a prisoner\n* Patient is a known alcohol or drug abuser\n* Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent",{"count":191,"type":20},820,"The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up\\*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.",[194,29,195,196,197],"Hip Arthritis","Hip Fractures","Hip Injuries","Hip Pain Chronic","2025-03-10",{"date":200,"type":42},"2025-03-11",{"date":202,"type":42},"2020-02-13",{"date":204,"type":20},"2032-02-12",{"name":206,"class":111},"Zimmer Biomet",3,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":86},"100527913","everglade-stem-world-cup-and-world-liner-post-market-clinical-follow-up-100527913","NCT06153940","Everglade Stem, World Cup and World Liner Post Market Clinical Follow-up","Inclusion Criteria:\n\n* patient requires unilateral primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, avascular necrosis, dysplasia\u002FDDH)\n* patient must be a candidate for use of the products studied, as determined jointly by the surgeon and patient\n* male and non-pregnant female patients aged 18-75\n* patients who understand the conditions of the clinical evaluation and are willing to participate for the length of the prescribed follow-up\n\nExclusion Criteria:\n\n* patient has active infection or sepsis(treated or untreated) enough to compromise implant stability or postoperative recovery\n* patient is a female of child-bearing age and not taking and not taking contraceptive pills\n* patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia)\n* patient has a known or suspected metal sensitivity\n* patient is immuno-suppressed with disease such as AIDS or is receiving high dose of cortico-steroids.\n* patient has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the clinical evaluation including mental illness, mental retardation or drug abuse\n* patient is severely overweight with a BMI\\>40.","75 Years",{"count":216,"type":20},200,"The aim of the Study is to monitor the performance of the Signature Orthopaedics Everglade Stem, World Acetabular Cup and World Liner as a part of post-market vigilance and continuous improvement efforts.",[29],"2023-11-22",{"date":221,"type":42},"2023-12-01",{"date":219,"type":42},{"date":224,"type":20},"2028-03-01",{"name":226,"class":111},"Signature Orthopaedics"]